Patients with a rare and aggressive type of blood cancer could soon have their chances of survival doubled as a groundbreaking trial to detect the disease earlier concludes.
Scientists working on the trial developed a highly sensitive test that that spots traces of disease in the bone marrow of patients to identify of acute myeloid leukaemia (AML).
